GreenLight Biosciences Holdings

$0.30-0.03%($-0.00)
TickerSpark Score
52/100
Mixed
80
Valuation
40
Profitability
15
Growth
76
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRNA research report →

52-Week Range2% of range
Low $0.18
Current $0.30
High $5.90

Companygreenlightbiosciences.com

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

CEO
Andrey Juan Zarur
IPO
2022
Employees
280
HQ
Medford, MA, US

Price Chart

-86.57% · this period
$4.16$2.17$0.18Jul 21Jan 20Jul 21

Valuation

Market Cap
$45.43M
P/E
-0.24
P/S
7.12
P/B
0.82
EV/EBITDA
-0.38
Div Yield
0.00%

Profitability

Gross Margin
100.00%
Op Margin
-2567.65%
Net Margin
-2616.78%
ROE
-1847.24%
ROIC
-126.46%

Growth & Income

Revenue
$6.38M · 0.00%
Net Income
$-167,055,000 · -45.61%
EPS
$-1.27 · -36.56%
Op Income
$-163,919,000
FCF YoY
-52.62%

Performance & Tape

52W High
$5.90
52W Low
$0.18
50D MA
$0.27
200D MA
$0.85
Beta
1.44
Avg Volume
684.80K

Get TickerSpark's AI analysis on GRNA

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Jul 24, 23KODIAK VENTURE PARTNERS III LPother9,809,895
May 29, 23KODIAK VENTURE PARTNERS III LPother0
Jul 24, 23Clarke Dennis A.other25,510.204
Jul 24, 23Anderson Eric Seniorother25,510.204
Jul 24, 23Cummings Foundation, Inc.other1,275,510.204
Jul 24, 23COONEY CHARLES Lother305,314
Jul 24, 23Insud Pharma S.L.other2,551,020
May 29, 23MLS Capital Fund II LPother0
Jul 24, 23MLS Capital Fund II LPother5,818,575
Jul 24, 23PATRICK DEVAL Lother172,500

Our GRNA Coverage

We haven't published any research on GRNA yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate GRNA Report →

Similar Companies